Formerly known as GlaxoSmithKline, the pharmaceutical giant unveiled a scaled-down new brand.

Discussing the new logo, a spokesperson said: “Housed in a redesigned shape known as the ‘signal’, the dynamic new GSK logo always points the way ahead,” explains the brand in an article. “The identity system flexes, adapts, and moves to engage audiences across all the digital, social and physical environments that the brand will appear in.”

Formerly known as GlaxoSmithKline plc, GSK is a UK-based multinational pharmaceutical and biotechnology company that serves customers worldwide. The company was formed through a merger of Glaxo Wellcome and SmithKline Beecham in 2000, with Emma Walmsley as acting the current CEO and Jonathan Symonds as the chairperson of the company.

The company is currently focusing on four areas for its Research and Development sector: HIV, immunology, oncology, and infectious diseases. In 2014 GSK made strides in the pharmaceutical industry by creating the first malaria vaccine, RTS-S. Another milestone the company reached was one of its consumer brands, Sensodyne, reaching £1 billion in sales in 2016.

GSK was listed as the sixth-largest pharmaceutical company by Forbes back in 2019 and was hailed as the tenth-largest biggest pharmaceutical company in Fortune 500, making it #296 on the list. The company has reached a revenue of £34.114 billion last year.